vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $11.5M, roughly 1.6× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs 9.8%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-11.8M). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs 3.5%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
ENTA vs TACT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $11.5M |
| Net Profit | $-11.9M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -60.5% | -10.1% |
| Net Margin | -64.1% | — |
| Revenue YoY | 9.8% | 11.9% |
| Net Profit YoY | 46.4% | — |
| EPS (diluted) | $-0.42 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $11.5M | ||
| Q3 25 | $15.1M | $13.2M | ||
| Q2 25 | $18.3M | $13.8M | ||
| Q1 25 | $14.9M | $13.1M | ||
| Q4 24 | $17.0M | $10.2M | ||
| Q3 24 | $14.6M | $10.9M | ||
| Q2 24 | $18.0M | $11.6M | ||
| Q1 24 | $17.1M | $10.7M |
| Q4 25 | $-11.9M | — | ||
| Q3 25 | $-18.7M | $15.0K | ||
| Q2 25 | $-18.3M | $-143.0K | ||
| Q1 25 | $-22.6M | $19.0K | ||
| Q4 24 | $-22.3M | — | ||
| Q3 24 | $-28.8M | $-551.0K | ||
| Q2 24 | $-22.7M | $-319.0K | ||
| Q1 24 | $-31.2M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | -60.5% | -10.1% | ||
| Q3 25 | -121.6% | 0.1% | ||
| Q2 25 | -103.2% | -1.9% | ||
| Q1 25 | -164.3% | -0.1% | ||
| Q4 24 | -138.8% | -10.3% | ||
| Q3 24 | -204.4% | -7.7% | ||
| Q2 24 | -134.6% | -3.8% | ||
| Q1 24 | -192.1% | -12.2% |
| Q4 25 | -64.1% | — | ||
| Q3 25 | -123.6% | 0.1% | ||
| Q2 25 | -99.7% | -1.0% | ||
| Q1 25 | -151.7% | 0.1% | ||
| Q4 24 | -131.4% | — | ||
| Q3 24 | -197.3% | -5.1% | ||
| Q2 24 | -126.1% | -2.8% | ||
| Q1 24 | -182.7% | -9.7% |
| Q4 25 | $-0.42 | $-0.11 | ||
| Q3 25 | $-0.88 | $0.00 | ||
| Q2 25 | $-0.85 | $-0.01 | ||
| Q1 25 | $-1.06 | $0.00 | ||
| Q4 24 | $-1.05 | $-0.80 | ||
| Q3 24 | $-1.36 | $-0.06 | ||
| Q2 24 | $-1.07 | $-0.03 | ||
| Q1 24 | $-1.47 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $31.1M |
| Total Assets | $329.5M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $20.4M | ||
| Q3 25 | $32.3M | $20.0M | ||
| Q2 25 | $44.8M | $17.7M | ||
| Q1 25 | $60.2M | $14.2M | ||
| Q4 24 | $84.3M | $14.4M | ||
| Q3 24 | $37.2M | $11.3M | ||
| Q2 24 | $35.8M | $11.1M | ||
| Q1 24 | $63.5M | $10.6M |
| Q4 25 | $126.6M | $31.1M | ||
| Q3 25 | $64.7M | $31.8M | ||
| Q2 25 | $79.3M | $31.3M | ||
| Q1 25 | $93.5M | $30.9M | ||
| Q4 24 | $111.8M | $30.6M | ||
| Q3 24 | $128.8M | $38.4M | ||
| Q2 24 | $148.9M | $38.5M | ||
| Q1 24 | $166.1M | $38.6M |
| Q4 25 | $329.5M | $44.8M | ||
| Q3 25 | $280.7M | $45.0M | ||
| Q2 25 | $301.0M | $44.5M | ||
| Q1 25 | $323.0M | $44.2M | ||
| Q4 24 | $348.6M | $44.0M | ||
| Q3 24 | $376.7M | $50.5M | ||
| Q2 24 | $398.8M | $50.4M | ||
| Q1 24 | $413.6M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $609.0K |
| Free Cash FlowOCF − Capex | $-11.8M | $589.0K |
| FCF MarginFCF / Revenue | -63.6% | 5.1% |
| Capex IntensityCapex / Revenue | 0.8% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $609.0K | ||
| Q3 25 | $-6.5M | $3.6M | ||
| Q2 25 | $17.5M | $3.6M | ||
| Q1 25 | $-13.5M | $-161.0K | ||
| Q4 24 | $-16.8M | $2.4M | ||
| Q3 24 | $-10.4M | $327.0K | ||
| Q2 24 | $-14.8M | $636.0K | ||
| Q1 24 | $-28.6M | $-1.5M |
| Q4 25 | $-11.8M | $589.0K | ||
| Q3 25 | $-7.9M | $3.6M | ||
| Q2 25 | $17.4M | $3.6M | ||
| Q1 25 | $-16.0M | $-171.0K | ||
| Q4 24 | $-25.5M | $2.4M | ||
| Q3 24 | $-19.4M | $259.0K | ||
| Q2 24 | $-21.3M | $499.0K | ||
| Q1 24 | $-30.3M | $-1.6M |
| Q4 25 | -63.6% | 5.1% | ||
| Q3 25 | -52.5% | 27.1% | ||
| Q2 25 | 94.7% | 25.9% | ||
| Q1 25 | -107.4% | -1.3% | ||
| Q4 24 | -150.6% | 23.2% | ||
| Q3 24 | -132.5% | 2.4% | ||
| Q2 24 | -118.6% | 4.3% | ||
| Q1 24 | -177.5% | -14.9% |
| Q4 25 | 0.8% | 0.2% | ||
| Q3 25 | 9.6% | 0.5% | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 17.0% | 0.1% | ||
| Q4 24 | 51.6% | 0.1% | ||
| Q3 24 | 61.3% | 0.6% | ||
| Q2 24 | 36.4% | 1.2% | ||
| Q1 24 | 9.8% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
